A PDE4 inhibitor Zatomilast® is currently in Phase III Clinical Trials for the treatment of cognitive deficits produced by Alzheimer’s disease and Fragile-X Syndrome, further demonstrating the importance of activating the cAMP/PKA pathway. The gene discussed is PDE4A; the disease is fragile X syndrome.